Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Income from Continuing Operations of 53458000.0 for Q1 2026, up 21.38% year-over-year from 44043287.4 in Q1 2025, and up 10.01% quarter-over-quarter from 59402000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 53458000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 21.38% year-over-year to 53458000.0; the TTM figure through Mar 2026 stood at 222346000.0 (up 13.84% YoY), while the FY2025 annual figure was 236880000.0, up 2.83% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 53458000.0, up from 59402000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 30886000.0 in Q3 2022, with the low at 171895000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 56755000.0 (2025), against an average of 65041400.0.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 71.69% in 2023, then jumped 45.78% in 2024.
- Neumora Therapeutics' Income from Continuing Operations stood at 171895000.0 in 2022, then soared by 36.9% to 108462000.0 in 2023, then jumped by 45.78% to 58810000.0 in 2024, then declined by 1.01% to 59402000.0 in 2025, then grew by 10.01% to 53458000.0 in 2026.
- Business Quant data shows NMRA's Income from Continuing Operations at 53458000.0 in Q1 2026, 59402000.0 in Q4 2025, and 56755000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -53.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.40 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -67.99 Mn |
| Dec 31, 2024 | -58.81 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -108.46 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -38.69 Mn |
| Dec 31, 2022 | -171.90 Mn |
| Sep 30, 2022 | -30.89 Mn |